Mathew J M, Carreno M, Zucker K, Fuller L, Kenyon N, Esquenazi V, Ricordi C, Tzakis A G, Miller J
Department of Surgery, University of Miami School of Medicine, Florida 33136, USA.
Transplantation. 1998 Apr 15;65(7):947-55. doi: 10.1097/00007890-199804150-00015.
The cascade of immunological effects brought about by donor bone marrow cell (DBMC) infusions in human organ transplantation, especially in the context of continuous pharmacologic immunosuppression, is not fully understood. Yet, in inbred rodents and even primates, administration of specific bone marrow cells has caused a state of acquired immunologic tolerance.
In vitro mixed lymphocyte culture (MLC) and cell-mediated lympholysis (CML) culture systems were used to compare the responding and regulatory properties of DBMC and individual bone marrow cell subsets versus spleen cells in the presence or absence of pharmacologic immunosuppression.
In the absence of immunosuppressive drugs, the DBMC proliferated in MLC and in response to phytohemagglutinin, but to a lower magnitude than donor spleen cells. In CML assays, DBMC failed to function as cytotoxic cells. Removal of both CD3+ and CD34+ cells together (not just singly) had to occur for complete abrogation of the proliferative response of DBMC evoked in the presence of allogeneic stimulating cells. Testing several experimental variables using flow cytometric analysis led to the conclusion that when purified DBMC CD34+ cells were placed in coculture with irradiated allogeneic peripheral blood mononuclear cells, such CD34+ cells give rise both to CD3- TCRalphabeta+ as well as to dimly staining CD3+ TCRalphabeta+ cells. Low pharmacologic concentrations of tacrolimus/cyclosporine (CsA) and mycophenolic acid (MPA) singly or in combination had no effect on the spontaneous proliferation of DBMC and had significantly less inhibitory activity on MLC responses of DBMC and its purified CD3+ or CD34+ subpopulations, compared with the responses of spleen cells. Moreover, the previously described regulatory effects of DBMC on the MLC responses of peripheral blood or splenic responding cells were not inhibited by these immunosuppressive drugs.
Taken together, these results support the notion that in vitro DBMC subpopulations, which proliferate as responding cells in co-culture with x-irradiated allogeneic cells and which cause regulatory effects when added as a third component to MLC reactions, seem to be culture-generated lymphoid cell lineage(s) progeny of CD34+ cells. This possibly includes unique CD3+ "primitive" (dimly staining) T cells, which are not as inhibited in their function by tacrolimus/CsA and MPA, as are postthymic (splenic) T cells.
在人体器官移植中,尤其是在持续药物免疫抑制的情况下,供体骨髓细胞(DBMC)输注所引发的一系列免疫效应尚未完全明确。然而,在近交系啮齿动物甚至灵长类动物中,给予特定的骨髓细胞会导致获得性免疫耐受状态。
采用体外混合淋巴细胞培养(MLC)和细胞介导的淋巴细胞溶解(CML)培养系统,在有或没有药物免疫抑制的情况下,比较DBMC和单个骨髓细胞亚群与脾细胞的反应性和调节特性。
在没有免疫抑制药物的情况下,DBMC在MLC中以及对植物血凝素产生增殖反应,但增殖程度低于供体脾细胞。在CML试验中,DBMC不能作为细胞毒性细胞发挥作用。必须同时去除CD3+和CD34+细胞(而不仅仅是单独去除),才能完全消除在异基因刺激细胞存在下诱发的DBMC增殖反应。使用流式细胞术分析测试多个实验变量得出结论,当纯化的DBMC CD34+细胞与经辐照的异基因外周血单个核细胞共培养时,此类CD34+细胞会产生CD3 - TCRαβ+细胞以及染色较淡的CD3+ TCRαβ+细胞。低药理浓度的他克莫司/环孢素(CsA)和霉酚酸(MPA)单独或联合使用对DBMC的自发增殖没有影响,并且与脾细胞的反应相比,对DBMC及其纯化的CD3+或CD34+亚群的MLC反应的抑制活性明显较低。此外,先前描述的DBMC对外周血或脾反应细胞的MLC反应的调节作用不受这些免疫抑制药物的抑制。
综上所述,这些结果支持以下观点:体外DBMC亚群在与经X射线辐照的异基因细胞共培养时作为反应细胞增殖,并且在作为第三成分添加到MLC反应中时会产生调节作用,它们似乎是CD34+细胞培养产生的淋巴细胞谱系后代。这可能包括独特的CD3+“原始”(染色较淡)T细胞,其功能不像胸腺后(脾)T细胞那样受到他克莫司/CsA和MPA的抑制。